Goserelin
Goserelin is an FDA-approved GnRH receptor agonist. Goserelin is a synthetic decapeptide analog of GnRH delivered from a biodegradable implant. Continuous rather than pulsatile receptor occupancy first stimulates and then downregulates pituitary GnRH receptors, so an initial rise in gonadotropins and sex steroids is followed within about two to four weeks by sustained suppression to castrate concentrations.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 1269.4 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Depot GnRH receptor agonist approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablation.
Peptide Library's Goserelin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Goserelin is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C59H84N18O14 |
|---|---|
| Molecular weight | 1269.4 g/mol |
| PubChem CID | 5311128 |
| FDA UNII | 0F65R8P09N |
| ChEMBL | CHEMBL1201247 |
| DrugBank | DB00014 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Goserelin is a synthetic decapeptide analog of GnRH delivered from a biodegradable implant. Continuous rather than pulsatile receptor occupancy first stimulates and then downregulates pituitary GnRH receptors, so an initial rise in gonadotropins and sex steroids is followed within about two to four weeks by sustained suppression to castrate concentrations.
Studies
- Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial
- Roles of Goserelin in Gynecological Disorders
- Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review
- Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis
- Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex)
Regulatory & research status
Goserelin is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Goserelin: frequently asked questions
What is Goserelin?
Depot GnRH receptor agonist approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablation.
How does Goserelin work?
Goserelin is a synthetic decapeptide analog of GnRH delivered from a biodegradable implant. Continuous rather than pulsatile receptor occupancy first stimulates and then downregulates pituitary GnRH receptors, so an initial rise in gonadotropins and sex steroids is followed within about two to four weeks by sustained suppression to castrate concentrations.
Is Goserelin FDA approved?
Yes. Goserelin is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Goserelin?
Compounds most often compared with Goserelin include Leuprolide, Triptorelin, Nafarelin and Histrelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial — Chin Med J (Engl), 2023External reference
- Roles of Goserelin in Gynecological Disorders — Drug Des Devel Ther, 2026External reference
- Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review — BJU Int, 2018External reference
- Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis — Fertil Steril, 1998External reference
- Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex) — J Endocrinol, 1984External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Goserelin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Goserelin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →